TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

TPEX:4157 Revenue

TaiGen Biopharmaceuticals Holdings had revenue of 8.23M TWD in the quarter ending June 30, 2026, a decrease of -23.14%. This brings the company's revenue in the last twelve months to 256.46M, up 530.40% year-over-year. In the year 2025, TaiGen Biopharmaceuticals Holdings had annual revenue of 259.47M with 72.24% growth.

• Revenue (ttm): 256.46M
• Revenue Growth: +530.40%
• P/S Ratio: 25.45
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 6.53B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	259.47M	108.82M	72.24%
Dec 31, 2024	150.65M	27.52M	22.35%
Dec 31, 2023	123.13M	86.90M	239.87%
Dec 31, 2022	36.23M	-1.26B	-97.20%
Dec 31, 2021	1.29B	1.27B	5,426.95%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error